TUSTIN, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has been named a recipient of six 2018 Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers
with the industry's highest level of service. Now in its 7th year, Life Science Leader's CMO Leadership Awards aim to provide industry insiders with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.
Avid received awards in the following categories:
"We believe that one of the greatest competitive differentiators helping to drive the growth of Avid's CDMO business is the company's long-standing reputation for excellence within the industry. With the CMO Leadership Award winners selected, in part, based on surveys of customers of CDMO services, our receipt of six awards highlights the meaningful impact our focus on quality, reliability, capabilities, expertise, compatibility and service is having on industry sentiment," said Roger Lias, Ph.D., president and chief executive officer of Avid Bioservices. "We'd like to take this opportunity
to thank all of our employees who strive for excellence every day, as well as those individuals who championed Avid as being worthy of each of the CMO awards we received."
For more information about Life Science Leader's CMO Leadership Awards, please visit: http://cmoleadershipawards.com/.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived
from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Kelly Pisarev LordAvid Bioservices, Inc.
Stephanie Diaz (Investors)
Vida Strategic Partners
Tim Brons (Media)
Vida Strategic Partners
Source: Avid Bioservices, Inc
News Provided by Acquire Media